Keyphrases
Mantle Cell Lymphoma
100%
Peripheral Blood
100%
Complete Remission
100%
Ataxia Telangiectasia
100%
Splenic Irradiation
100%
Radiation Effects
33%
Intrinsic Radiosensitivity
33%
Clinical Features
16%
Lymphoma Cells
16%
B-cell non-Hodgkin Lymphoma (B-NHL)
16%
Working Diagnosis
16%
Response Rate
16%
Radiation Therapy
16%
Spleen
16%
Fluorescence in Situ Hybridization
16%
Histological Subtypes
16%
Disease Course
16%
Lymphoproliferative Disorders
16%
Well-defined
16%
Low Response
16%
Lymphoma Subtype
16%
Lymphocyte Subsets
16%
Aggressive Disease
16%
Molecular Features
16%
Chromosomal Region
16%
Predictive Marker
16%
Indolent Course
16%
Splenomegaly
16%
Clinical Subtypes
16%
Systemic Effects
16%
Palliative Treatment
16%
Lymphoid Cells
16%
Immune Regulation
16%
Cytokine Release
16%
Genetic Features
16%
In Vitro Data
16%
Radiosensitivity
16%
Apoptotic Cell Death
16%
Mutated Genes
16%
Direct Radiation
16%
Cytogenetic Aberrations
16%
Proportional Changes
16%
Moderate Dose
16%
Double-strand Breaks
16%
Advanced Stage Disease
16%
Radiation Response
16%
Radiation-induced DNA Damage
16%
Medicine and Dentistry
Mantle Cell Lymphoma
100%
Ataxia Telangiectasia
100%
Radiosensitivity
50%
In Vitro
16%
Programmed Cell Death
16%
Disease
16%
B Cell
16%
Radiation Therapy
16%
Allele
16%
Non-Hodgkin Lymphoma
16%
Clinical Feature
16%
DNA Damage
16%
Lymphoproliferative Disease
16%
Disease Course
16%
Fluorescence in Situ Hybridization
16%
Lymphocyte Subpopulation
16%
Splenomegaly
16%
Symptomatic Treatment
16%
Lymphoid Cell
16%
Immunomodulation
16%
Cytokine Release
16%
Predictive Marker
16%
Mantle Cell Lymphoma Cell
16%
Radiation Response
16%